IP
ABBV icon

Integras Partners’s AbbVie ABBV Stock Holding History

Integras Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.85M Buy
15,318
+411
+3% +$88.4K 2.13% 10
2026
Q1 		$3.24M Buy
14,907
+221
+2% +$49K 2.13% 18
2025
Q4 		$3.36M Sell
14,686
-1,400
-9% -$319K 2.71% 7
2025
Q3 		$3.72M Buy
16,086
+632
+4% +$129K 3.01% 7
2025
Q2 		$2.87M Sell
15,454
-110
-0.7% -$20.4K 2.89% 12
2025
Q1 		$3.26M Sell
15,564
-184
-1% -$35.8K 2.94% 5
2024
Q4 		$2.8M Buy
+15,748
New +$2.9M 2.39% 13

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Integras Partners's ABBV Position: Q2 2026 in Review

Integras Partners increased its AbbVie (ABBV) stake by 2.8% in Q2 2026, buying an estimated $88.4K and bringing the position to 15,318 shares worth $3.85M. The position accounts for 2.13% of the portfolio, ranked #10.

Integras Partners first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Integras Partners held 15,318 shares of AbbVie worth $3.85M as of Q2 2026.
  • Integras Partners bought 411 AbbVie shares in Q2 2026, an estimated $88.4K.
  • AbbVie made up 2.13% of Integras Partners's portfolio in Q2 2026, its #10 holding.
  • Integras Partners first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Integras Partners's 13F filing for Q2 2026, filed 24 Jul 2026.